Spain's Almirall opens affiliate in UK
Spain's largest drugmaker, Almirall, says it is continuing with its European expansion by establishing an affiliate in the UK. There, it recently acquired a portfolio of six products from domestic firm Shire for $213.0 million as well as a staff of 63 (Marketletter October 15, 2007). It is expected that the new unit, which will also be responsible for the group's Irish operations, will generate revenues of 30.0 million euros ($44.4 million) this year.
Almirall UK will also be commercializing the group's own R&D products, such as the anti-inflammatory Preservex (aceclofenac) and the migraine drug Almogran (almotriptan), as well as products from Hermal, the Germany-based dermatology business acquired for over $500.0 million; Marketletter September 10, 2007).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze